YL-15293 for Solid Tumors

Phase 1 & 2

Waitlist Available

Research Sponsored by Shanghai YingLi Pharmaceutical Co. Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up throughout the study for approximately 2 years

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new pill called YY-15293 in patients with a type of lung cancer that has a specific genetic change. The pill aims to stop the cancer from growing by targeting this change. Sotorasib was the first approved treatment for this type of lung cancer.

Eligible Conditions

Advanced Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ throughout the study for approximately 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~throughout the study for approximately 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and throughout the study for approximately 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

The overall response rate (ORR)

Secondary study objectives

Disease control rate, DCR

Overall survival, OS

Progression free survival, PFS

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: YL-15293Experimental Treatment1 Intervention

After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons. Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.

Do I qualify?Apply below to find out